Synthesis of C (6)-epimer derivatives of diacetoxy acetal derivative of santonin and their inducing effects on HL-60 leukemia cell differentiation

Riferimento: 
Arch Pharm Res. 2011 Feb;34(2):191-8.
Autori: 
Kweon SH, Kim KT, Hee Hong J, Kim TS, Choi BG.
Fonte: 
Arch Pharm Res. 2011 Feb;34(2):191-8.
Anno: 
2011
Azione: 
La combinazione di 1,25-diidrossi-vitamina D(3) [1,25-(OH)(2)D(3)] e acido all-trans retinoico (ATRA) può migliorare i risultati nella terapia della leucemia promielocitica acuta.
Target: 
1,25-(OH)(2)D(3) – ATRA/leucemia promielocitica acuta.

ABSTRACT
Induction of differentiation is a new and promising approach to leukemia therapy, well illustrated by the treatment of acute promyelocytic leukemia with 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] or all-trans retinoic acid (ATRA). Using combination of either 1,25-(OH)(2)D(3) or ATRA and chemotherapy, adverse effects 1,25-(OH)(2)D(3) or ATRA such as hypercalcemic effects have decreased, and long-term survival has improved. In a previous study, we demonstrated that santonin could be chemically modified into a diacetoxy acetal derivative of santonin with strong differentiation-inducing activity. In this study, we further synthesized C(6)-epimer derivatives of diacetoxy acetal derivative of santonin and tested their effects on HL-60 cell differentiation. Some of the C(6)-epimer derivatives themselves induced increases in cell differentiation. Especially, (11S)-3,3-(ethylenedioxy) eudesmano-13-ol-6β-acetate (7) was demonstrated to induce differentiation with larger than 80% of the cells attaining a differentiated phenotype. Importantly, 7 strongly enhanced differentiation of HL-60 cells in a dose-dependent manner when combined with either low doses of 1,25-(OH)(2)D(3) or ATRA. The ability to enhance the differentiation potential of 1,25-(OH)(2)D(3) or ATRA by 7 may improve outcomes in the therapy of acute promyelocytic leukemia.

Sostanze: